

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وزارة الصحة الاتحادية  
الإدارة العامة للصيدلة

الإستراتيجية الصيدلانية ربع القرنية

2005م - 2029م

-:

2.....		. I
4.....		. II
6.....		. III
10.....		.1
11 .....	1.1	
12.....	1.2	
12.....	1.3	
12.....	1.4	
13.....	1.5	
14.....		.2
15.....	2.1	
16.....	2.2	
17.....	2.3	
20.....		.3
24.....		.4
27.....		.5
30.....		.6
33.....		.7
36.....	7.1	
37.....	7.2	
38.....	7.3	
38.....	7.3.1	
38.....	7.3.2	
38.....	7.3.3	
39.....		.8
40..	8.1	

40.....	8.2	
41 .....	8.3	
42.....		.9
44.....		.10
45.....	10.1	
45.....	10.2	
47.....		.11
49.....	11.1	
51.....	11.2	
51.....	11.3	
52.....	11.4	
54.....		.12
56.....		.13

**تقديم معالي الدكتور وزير الصحة**

2003

2028 – 2004

55

2010 – 2006

---

---

	:	1
	..	2
	.	3
	.	4
	.	5
	.	6
	.	7
	.	8
	.	9
	.	10
	.	11
	.	12
	.	13
	.	14
	.	15
	.	16
	.	17
	..	18
	.	19
	.	20
	.	21
	.	22
	.	23
	.	24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

.	53
.	54
.	55
.	56
.	57
.	58
.	59
.	60
.	61
.	62
.	63
.	64
.	65
.	66
.	67
.	68
.	69
.	70
.	71
.	72
.	73
.	74
.	75



## الباب الأول



.2

2003  
10 . 4  
2003  
2003

( 2004 /9 /26-24 )

. 2005

.3

:

•

( )

( )

( )

( )

( )

:

-

-

-

.4

.5



## الباب الثاني

### الإطار التنظيمي لقطاع الصيدلة بالسودان

•  
•

.1

.2

.3

.4

.5

•  
•

•  
•

•  
•  
•  
•

•  
•

.1

.2

.3

.4

-

-

-

-

.Drug information Centers

•

1976

1963

( )

2001/8/20

.2001/12/8

1963

:

( ) (1)

1963

(2)

( ) (3)

(4)

(5)

(6)

1974

1963

1992

2001

.1

1.1

2.1

3.1

4.1

.	.2
.	.3
.	.4
.	.5
.( )	.6
( )	
.	

## الباب الثالث

### النظام الوطني لتوكيد جودة الأدوية

( )

:

.( )

(1)

.(Post Marketing Surveillance)

(2)

( )

.1

.2

.3

.4

( )

.1

( )

.2

.(GPP)

.3

.4

.5

( )

.1

.2

.3

.4

.5

( )

.ADR monitoring system

.1

.2

.3

## الباب الرابع

### التصنيع الدوائي

. 7  
23  
10 19  
:

Tablets, Capsules, Syrup, Suspensions, Powder, Ampoules, Ointments, Parenteral infusion.

5  
.  
%20  
8  
:  
.1  
.  
.2  
.  
.3  
.  
.4  
%71 %4  
250  
.

	.1
	.2
	.3
Multi National	.4
2016 (Transitional Period)	.5
	.6
	.7

## الباب الخامس

### الإستعمال الرشيد للدواء

		.1
		.2
Standard Treatment )	(National Formulary)	.3
	(Guidelines	.4
		.5

.6

.7

.8

.9

Antimicrobial Resistance Surveillance

.10

.11

( )

.12

( )

( )

( )

## الباب السادس

### الطب الشعبي

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)



## الباب السابع

### الأداء المهني الصيدلي

Retention of pharmacists in the )

(public sector

:

:

-

:

(1)

:

(2)

:

(1)

(2)

(3)

(4)

(5)

(6)

⋮

%60

...

⋮

(1)

(2)

(3)

.Compliance

(4)

(5)

(6)

⋮

(1)

(2)

(3)

:

"Dispensing"

"Discharge Clinics"

:

.(Hospital Drug Formulary)

(1)

(2)

(3)

(4)

(5)

(6)

(7)

:

(1)

.

(2)

.

(3)

.

(4)

.

(5)

.

:

:

(1)

.

(2)

.

.

(3)

:

.

:

.

•

.

•

.

•

## الباب الثامن

### التعليم الصيدلي والتطوير المهني المستمر

2350

.1

:

( )

( )

( )

( )

.2

:

( )

:

( )

( )

( )

( )

.3

:

.Continuing Professional Development (CPD)

Continuing Education

:

(1)

(2)

## الباب التاسع

### الدراسات والبحوث

:

.1

( )

( )

( )

( )

.2

## الباب العاشر

### الممارسة المهنية و آداب السلوك المهني

.1

( )

:

Principles

-

Obligations

-

Guidance on obligations

-

.2

:

:

()

•

:

( )

.

:

( )

.

.

## الباب الحادى عشر

### الإمداد الدوائى

1997

(1995)

)

%30

%70

(

(Quick 1997) %50

) %5

121 (2001 )

%95

75

%29.5

(

(2003

:

-

-

-

-

:

(1)

(2)

(3)

(4)

:

(1)

( )

(2)

(3)

(Direct )

Delivery System

:

)

(

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

(TENDER BOOK)

(13)

(14)

(15)

(16)

:

(1)

(2)

(3)

(4)

(5)

:

•

•

•

:(

)

TRIPS (( ))

:

•

(( ))

•

:

:

(1)

(2)

(User Fee)

(3)

## الباب الثاني عشر

:		
(	)	.1
.		.2
.		.3
.		.4
.		.5
.		.6
.	"Patients Compliance"	.7
.		.8
.		.9
.		.10
.		.11
.		.12

	.13
.	.14
.	.15
.	.16
.	.17
.	.18
.	.19
.	.20
.Counterfeit Medicines	
.	.21
.	.22

## الباب الثالث عشر

## المراجع

### References:

- 1 *A strategy for pharmacy's Medicines Information service in the NHS. Implementation Framework UKMI. August 2000.*
- 2 Abraham J. the pharmaceutical industry as a political player. *The lancet* 2002;360 : 1498-1502
- 3 Adu A, etal. Attitudes of pharmacists and physicians to antibiotic policies in hospitals. *Journal of clinical pharmacy and therapeutics* 1999; 24:181-189.
- 4 Anderon C, health promotion in community pharmacy: *the UK situation. Patient education and counseling* 2000 ; 285-291
- 5 Ascione F, etal. Historical overview of Generic medication policy. *Journal of the American pharmaceutical Association* 2001; 41 (4): 567-577.
- 6 Ask your pharmacist .*Careers information 2001 www.askyourpharmacist.co.uk/carres.html*
- 7 Audit commission a spoonful of sugar: *medicines management in NHS hospitals .2001; Audit commission. London; UK*
- 8 Avery AJ, etal. A prescription for improvement? An observational study to identify how general practices vary in their growth in prescribing cost. *BMT* 2000; 321:276-281
- 9 Baladi JF, etal . Use of economic evaluation guidelines : *2years experience in Canada .health economics* 1998 ; 7: 221-227
- 10 Banta D. increase in global access to essential drugs sought. *JAMA*2000;183(3):321
- 11 Banta D. worldwide interest in global access to drugs *JAMA*2001;285 (22): 2844-2846
- 12 Barber N. pharmaceutical care and medicines management is there a difference ?*Pham World Sci* 2001 ; 23(6) : 210-21.
- 13 Bardelelay D, Kopp C, commentary: *concern over drug industries influence on registration .BMJ* 2001;322 :920-923
- 14 Bellingham C. pharmacy: From vision to reality. *The pharmaceutical Journal* 2001; 266:861
- 15 *Better Information for managing medicines: A strategy for pharmacy's Medicine Information Service in the NHS. UK Medicine information. April 2000.*
- 16 Bjerrum L, Bergman U. Wide Variation in the number of different drugs prescribed by general practioners. *A prescription database study. Scand J Prim Health Care* 2000; 18: 94-98.
- 17 Bond CA, etal. Clinical pharmacy services, hospital pharmacy staffing and medical errors in United States hospitals. *Pharmacotherapy* 2002; 22 (2)
- 18 Bowden J, etal . Benchmarking clinical pharmacy services . (1) *developing the standards . The pharmaceutical Journal* 2001 ; 267 : 60-65
- 19 Bussieres JF, Lefebvre P. Canada, Hospital Pharmacy Practice: *A Canadian perspective. Int. Pharmacy Journal* 2002; 16 (1): 11-13
- 20 Cantrill JA. Measuring the appropriateness of long-term prescribing in United Kingdom general practice- Is the British National Formulary The Gold Standard ?. *Journal of clinical pharmacy and therapeutics* 2000; 25:341- 346
- 21 Charatan F. Medical errors kill almost 100000 Americans a year. *BMJ* 1999; 319: 1519.
- 22 Clark JS, Vermeulen LC. Hospital pharmacy in the United States. *Int. Pharmacy Journal* 2002; 16(1): 18-19.
- 23 Collier J, Iheanacho I. the pharmaceutical industry as an informant. *the lancet* 2002 ; 360:1405-1409
- 24 Cross As .best practice in therapeutic drug monitoring .*BMJ*1998 ;46((2):95
- 25 Danzon PM. Marking sense of drug process . *Regulation* ; 23(1):56-63
- 26 Dean B, etal . Causes of prescribing errors in hospital inpatients :*a perspective study. The lancet* 2002 ; 359 : 1373-1378
- 27 Devries, TPGM, Henning R, Hogerzeil HV, Fresle DA, Guide to good prescribing . *A practical Manual. Geneva :world health orgnization;1994-WHO/DAP/94-11.*

- 28 Dukes MN. Accountability of the pharmaceutical industry , the lancet 2002 ; 360 : 1682-1684
- 29 Edmunds J, Calnan M, the reprofessionalisation of community pharmacy? An exploration of attitudes to extended roles for community pharmacists amongst pharmacists and General practioners in the United King. *social science & medicine* 2001; 53:943-955.
- 30 EMEA, The European Agency for the evaluation of medicinal products. The EMEA code of conduct. London: EMEA/D/37674/99 <http://www.eudra.org/emea.html>.
- 31 Eronen M, Nylander M. Hospital pharmacy practice in Finland. *Int. pharmacy journal* 2002; 16 (1): 32-34.
- 32 Evans JM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland .*Br J pharmacol* 1999 ; 47 : 105-110
- 33 Fattore G, Jommi C. the new pharmaceutical policy in Italy .*health policy* 1998 ; 46 : 21-41
- 34 Fijn R, etal . Hospital prescribing errors :*epidemiological assessment of predictors* .*BrJ clin pharmacol* 2002; 53:326-331.
- 35 Fleming A. On the bacterial action of culture of a penicillin, with special reference to their use in the isolation of B. influenzae . *The British Journal of Experimental pathology* 1929 ; 10 : 226-236 . *Republished – Bulletin of the world health organization* 2001 ; 79(8) : 780-790
- 36 Fonseca GL, Montero N. Hospital Pharmacy practice in Costa Rica. *Int. pharmacy journal* 2002; 16(1): 27-31.
- 37 Freemantle N, etal . Sleeping with the enemy ?A randomized controlled trial of a collaborative health authority / industry interventaion to influence prescribing practice .*Br J clin pharmacol* 2002 ; 49 : 174-179
- 38 GAO: Prescription drugs .FDA oversight of direct-to-consumer. Advertising has limitations .*report to congressional requesters* 2002 .*www.gao.gov*
- 39 Gilson L, etal. Strategies for promoting equity: *experience with community financing in three African countries*. *Health Policy* 2001, 58:37-67.
- 40 Giuliani G, selke G, Garattini L, the German experience in reference pricing. *Health policy* 1998;44:73-85
- 41 Gottlieb S. is the FDA approving drugs too Fast? Probably not .but drug recalls have sparked debate. *BMJ* 1998;317:899
- 42 Grand AL, etal . Intervention research in rational use of drugs: a review health policy and planning 1999 ; 14 (2) : 89-102
- 43 Grattini L, Tediosi F, A comparative analysis of generics markets in five European countries .*health policy* 2000 ; 51 : 149 – 162
- 44 Gray A. Health systems pharmacy in South Africa, opportunities for growth and leadership. *Int. Pharmacy Journal* 2002; 16 (1) 13-17.
- 45 Green CF , etal . Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. *BrJ Clin pharmacol* 2001;51:81-86
- 46 GREEN CF, Mottram DR, Pirmohamed M, Morner R, ROWE PH, communication regarding adverse drug reaction between secondary and primary care: *a postal questionnaire survey of general Practioners Journal of clinical pharmacy and therapeutics* 1999; 24:133-139
- 47 Greenhalgh T. Effective prescribing at practice level should be identified and rewarded. *BMJ* 1998; 316: 750-753.
- 48 Gruskin S. Loff B, Do human rights have a role in public health work ? *The lancet* 2002 360 :1880
- 49 Guiding principles for drug use at the patient and population levels. Statement of scientific policy , council of experts information executive committee . *United State pharmacopoeia . J Am Pharm Assoc .* 2001 ; 41(4):513
- 50 Hall peter. Doctors urgently need education in human rights . *the lancet* 2002 ; 360 : 1879
- 51 Harmsworth K, Lewith GT. Attitudes to traditional Chinese medicine amongst Western trained doctors in the People's Republic of China. *Social Science and Medicine* 2001; 52:149-153.
- 52 Hassel K, etal. Managing ,demand: transfer of management of self limiting conditions from general reactive to community pharmacies. *BMJ* 2001;323:146-147
- 53 Henry D, lexchin J . The pharmaceutical industry as a medicines provider. *The lancet* 2002 ; 360 : 1590-1595
- 54 Hollio A. the importance of being first: evidence from Canadian generic pharmaceuticals .*health Econ .* 2002 ; 11 : 723-724.
- 55 John A, show JP. Community pharmacists , perspective on pharmaceutical care implementation in Newzeland. *pharm world Sci* 2002 ; 24(6):224-230

- 56 John Abraham . Making regulation responsive to commercial interests: *streamlining drug industry watchdogs* *BMJ*2002;325:1164
- 57 Josefon D. drug companies face pressure on profile. *SMJ* 2002;324 : 65.
- 58 Jung H. Hospital Pharmacy in Mexico. *Int Pharmacy Journal* 2002; 16(1) 23-25.
- 59 Kahns AH, Nielsen G. Hospital pharmacy practice in Denmark. *Int pharmacy journal* 2002; 16(1): 34-37.
- 60 Kansanaho H. etal. Patient counseling profile in a finish pharmacy. *patient education and counseling* 2002; 47 : 77-82
- 61 Kindermans JM, Matthys F. introductory note: *the access to essential medicines campaign* . *Tropical medicine and international health* 2001, 6(11):955-956
- 62 Kirking DM, etal . Economics and structure of the generic pharmaceutical industry .*J Am pharm Assoc* .2001 ; 41(4) : 578-584
- 63 Kmietowicz 2. Medicines Control Agency must be more open .*BMJ* 2003; 326:119
- 64 Kumar S. Drug linked to child deaths is still available in India .*BMJ* 2003; 326:70
- 65 Laaksonen R, etal Desire for information about drug: *relationship with patients characteristics and adverse effects*. *Pharm world Sci* 2002;24(5):205-210
- 66 laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendation to improve use of medicines in developing countries. *Health policy and planning* 2001;16(1):13-20
- 67 Lakshmi PK, etal. The Changing Status of Hospital Pharmacy Practice in India. *Int pharmacy Journal* 2002; 16(1): 20-23.
- 68 Layton D, etal . Pharmacovigilance of over-the-counter product based in community pharmacy :methodological issues from pilot work conducted in Hampshire and Grampian UK. *Pharmacoepidemiology and drug safety* 2002 ; 11 : 503-513.
- 69 Leape LL, etal .Pharmacist participation on physician rounds and adverse drug events in the intensive care unit . *JAMA* 1999 ; 281(3) : 267-270 .
- 70 Lo B, Alpers A. uses and abuses of prescription drug information in pharmacy benefits management programs. *JAMA*2000;283(6):801-806.
- 71 Loff B. No agreement reached in talk on access to cheap drugs .*the lancet* 2002 ; 360 : 1951
- 72 Lopert R, etal . Differential pricing of drugs: *a role for cost effectiveness analysis ?* *The lancet* ; 359 : 2105-2107
- 73 Lopez-Casasnovas G , Puig-Junoy J, Review of the literature on reference pricing. *Health policy* 2000; 54:87-123.
- 74 Majeed A, Head S. *Capitation based prescribing budgets will not work*. *BMJ* 1998; 316 748-750
- 75 Maselli JH, etal. Pharmacoepidemiology report, Measuring antibiotic prescribing practices among ambulatory physicians: *Accuracy of administrative claims data*. *Journal of clinical epidemiology* 2001; 54: 196-201
- 76 Mc Letten F. Us government report released on deceptive drug advertisement: *The lancet* 2002 ; 360 :1951
- 77 MeG ettigan P. etal . Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message .*Br J clin pharmacol* ;51:184-189
- 78 Mert OM, etal . Direct to consumer advertising is medicalising normal human experience. *BMJ* 2002; 324 : 910-911
- 79 Mobach MP. From the laboratory to pharmaceutical care research -*part 1* *pharm world Sci* 2001 ; 23(6) : 205 - 209
- 80 Mobach MP. Pharmaceutical care research: Hard or soft ?*part 2* . *Pharm world Sci* 2002 ; 24 (1) : 1 - 4
- 81 Modernising medicines management: *A guide to achieving benefits for patients, professionals and the NHS (book1)*. 2001; *national prescribing center and national primary care research and development center* . London .UK.
- 82 Moen E, etal . Pricing and reimbursement of pharmaceuticals . A new culture for the community pharmacist. *pharm world management Sci* 1998 ; 20 (3): 107-112
- 83 Morgall JM, Almarsdottir AB. NO struggle, no strength :*how pharmacists lost their monopoly*. *Social science & medicine* 1999;48 1247-1258.
- 84 MSH . Rational Pharmaceutical Management project 2001 .[www.msn.org/project/rpm/tools.html](http://www.msn.org/project/rpm/tools.html)
- 85 Nabeshima Thasegawa M. Hospital Pharmacy in Japan. *Int.pharmacy Journal* 2002; 16 (1): 6-10.
- 86 Nair KV, etal. An organizational tool to describe and evaluate group performance in the health care setting. *Jam pharm Assoc*. 2001; 41 (4): 608-617.
- 87 Orbinski J. market enticements are not enough. *Bulletin of the world health organization* 2001 ; 79(8) : 776-777

- 88 Pecoul B, chirac P, trouiller P, pinel J. Access to essential drugs in poor countries A lost Battle? *JAMA* 1999; 281(4):361-367.
- 89 Perez-casas C, Herranz E, Ford N. Pricing of drug and donations: Options for sustainable equity pricing. *Tropical medicine and international health* 2001;6(11):960-964.
- 90 Peterson GM, et al. Pharmacists' attitudes towards dispensing errors: Their causes and prevention. *Journal of clinical pharmacy and therapeutics* 1999; 57-71.
- 91 Pharmacist prescribing. A report to health ministers . UK 2001 .[www.rpsgb.org](http://www.rpsgb.org)
- 92 Pitaknetinan K, Tangcharoensathien V, Supachutikul A, Bemmeth S, Mills A. Profit, payment and pharmaceutical practices: Perspectives from hospitals in Bangkok. *Health policy* 1999;46:179-194.
- 93 Pollock AM, Price D. . Rewriting the regulations: How the world trade organization could accelerate privatization in health-care system .*the lancet* 2002 ; 2000 ; 356 : 1995-2000
- 94 Primary care pharmacists. *National prescribing center and NHS executive* 1999. London.UK.
- 95 Principles of practice for pharmaceutical care .2001 .<http://www.aphanet.org/pharmacare/pronprace.html>
- 96 Pronk M, et al. Community pharmacy and patient-oriented activities . The Dutch case . *Patient education and Counseling* 2002 ; 46 :39-45
- 97 *Proposal for the establishment of the drug information center – Department of Pharmacy – MoH – KS, 2000.*
- 98 Propper C, Soderlund N. Competition in the NHS internal market : an overview of its effect on hospital prices and cost. *Health ECO.* 1998 ; 7 : 187-197
- 99 Qualified person in the pharmaceutical industry. Institute of Biology Royal pharmaceutical Society of Great Britain & Royal Society of chemistry. Guide to the knowledge and practical experience required by qualified persons in the pharmaceutical industry, *study guide* 2000. Version 1.
- 100 Quick JD, et al .Managing Drug Supply .2nd ed .west hatford , USA. Kumarian press;1997
- 101 Quick JD, Hogerzeil H, Vekasqyez G, Ragol. Twenty-five years of essential medicines .*Bulleting of the world health organization*2002;80(11):913-914
- 102 Quik JD. Partnership need principles .*Bulletin of the world health organization* 2001 ; 79 (8) : 776
- 103 Ratanawijitrasin S, et al . Do national drug policies and essential drug programmes improve drug use ? A review of experiences in developing countries . *Social science medicines* 2001 ; 53 : 831-844
- 104 Real world pharmacy: Assessing the quality of private pharmacy practice in the Laos people's Democratic Republic. *Social science and medicine* 2001 ; 52 : 393-404
- 105 Reeve JF, et al. Programme to improve the use of drugs in older people involve general practitioners in community education. *Journal of clinical pharmacy and therapeutics* 1999; 24: 289-297.
- 106 Roberts I, Wanpo AL, Chalamers I, intellectual property , drug licensing , freedom of information , and public health . *The lancet* 1998 ; 352 : 726-729
- 107 Rogers A, European parliament approves pharma law overhaul .*the lancet* 2002 ; 360(?):1397-1398
- 108 Royal pharmaceutical society of Great Britain .Building the future: A strategy for a 21st century pharmaceutical services . *Royal pharmaceutical society of Great Britain*1997
- 109 Royal pharmaceutical Society of Great Britain .*professional standard directorate Fact sheet : six Advertising .* [www.rpsgb.org](http://www.rpsgb.org)
- 110 Scala D, et al . Italian drug information center: Benchmark report. *Pharm world Sci* 2001 ; 23(6):127-223
- 111 Schirm E, et al . Drugs use of children in the community assessed through pharmacy dispensing data . *Br J clin pharmacol* 2000 ; 20 : 473-478
- 112 Schnurrer JU, et al . Drug expenditure in hospitals: What do German ward physicians know? *Br J clin pharmacol* 2000 ;51 : 342-344
- 113 Shanlian HU, et al . Pharmaceutical cost-containment policy: Experience in Shanghai , china . *health policy and planning* 2001 ; 16(2) ;4-9
- 114 Short C. report to prime minister: *UK working group on increasing access to essential medicines in the developing world .policy recommendations and strategy.* Nov2002
- 115 Slobodan M, et al .An analysis of drug use indicators in primary care health facilities operating in the city of Kragujevac.2001 .<http://www.priory.com/fam/kosovo.html>
- 116 Smecka V, Gasim I; Neuwirth O, Faculty of pharmacy . University of Khartoum: *development in Sudan* .*Sudan pharmacy* 1967; 1(5) :11-23

- 117 Somerset M, et al. Dramaturgical . Study of meetings between several practioners and representative of pharmaceutical companies.2001;323:1481-1484
- 118 Spivey RN. Etal 1992. international pharmaceutical services. The drug industry and pharmacy practice in Twenty - three major countries of the world . *New Yourk .London Norwod (Australia) . Pharmaceutical products press*
- 119 Sudan National Comperhensive Strategy: 1992- 2002
- 120 Sudan National Drug Policy 1997
- 121 Sudan Pharmacy and Poisons Act 2002
- 122 Sykes R. penicillin: From discovery to product.*Bulletin of the world health orgnization 2001 ; 79(8) : 778-779*
- 123 The national strategy for quality use of medicines - Australia .*health and aging .www*
- 124 The right medicine: A strategy for pharmaceutical care in Scotland. *Scotish executive*
- 125 Thielke T. FIP, The Hospital pharmacy section. *International pharmacy Journal 2002; 16(1): 2-5.*
- 126 Trap B, etal . The impact of supervision on stock management and adherence to treatment guidelines : *a randomized controlled trial . Health policy and planning 2001 ; 16(3)273-180*
- 127 Uzochukwu B, etal . Effect of the bamako- initiative drug revolving fund on availability and rational use of drugs in primary health care facilities in south-east Nigeria. *Healthy policy and planning 2002 ; 17(4) :378-383*
- 128 Vermeire E, Hearnshow H, van Royen P, denekens J, patient adherence to treatment:three decades of research. A comprehensive review.*Journal pf clinical pharmacy and therapeutic,2001;26:331-342*
- 129 Walley T. etal . An integrated national pharmaceutical policy for the united Kindom? *BMJ2000; 321 : 1523-1526*
- 130 Wazana A, phaysicians and the pharmaceutical industry as a gift ever just a gift ?*JAMA 2000; 283(3) : 373-380.*
- 131 Weingart S, etal. Epidemiology of medical error. *BMJ 2000; 320:774-777.*
- 132 WHO . Traditional medicines - Growing needs and potential , *WHO policy perspectives on medicines 2002 ; 2 : 1-5.WHO /EDM/2002.4.*
- 133 WHO counterfeit drugs- :guidelines for the development of measures to combat counterfeit drug. *Geneva : world health orgnization;1999.WHO/EDM/QSM/19901.*
- 134 WHO Guidelines for drug donations, 2nd ed .interagency guidelines. *Geneva, world health orgnization;1999. WHO/EDM/PAR 99.4*
- 135 WHO Medicines strategy :*frame work for action in essential drugs and medicines policy 2000-2003 ;Geneva WORLD worlz health organization; 2000.WHO/EDM/2000.1*
- 136 WHO strategy materials for pharmaceutical products: *Control and safe trade . Geneva : world health organization ; 1998 . WHO/pharm/98.6055*
- 137 WHO the role of the pharmacists in self-care and self-medication. report of the 4th Who Consultative group on the pharmacists .*Geneva :world health organization ;1998. WHO/DAP/98.13.*
- 138 WHO. Certification scheme on the quality of pharmaceutical products moving in international commerce . *Geneva: world health orgnization;1997.WHO/PHARM/80.4.*
- 139 WHO. Guidelines for the safe disposal of unwanted pharmaceuticals in and after emergencies. interagency guidelines. *Geneva :world heath orgnization;1999. WHO/EDM/PAR/199.2*
- 140 WHO. How to develop and implement a national drug policy .*2nd ed .Geneva: world health orgnization,2001*
- 141 WHO. Public - private Roles in the pharmaceutical sector . *specifications for equitable access and rational drug use . Geneva WHO 1997 . WHO/DAP/97.12.*
- 142 WHO. Ethical criteria for medicinal drug promotion .*Geneva :world health orgnization.1988*
- 143 Wick JY, Zanni R informed consent : what every pharmacist should know. *J Am pharm Assoc . 2001 ; 41(4) : 523-527*
- 144 Williams D, Kelly A, Feely J. Drugs interactions avoided-a useful indicator of good prescribing practice . *Br J clim pharmacol ; 49 : 369 - 372*
- 145 Yap P. Hospital Pharmacy Practice in Singapore. *Int. Pharmacy Journal 2002; 16(1): 25-27.*
- 146 Zweygarth M, Summers RS. A national database for essential drugs in South Africa .*pharm world Sci 2000 ; 22(3) :116-117*

